{"id":"epclusa-sof-vel","safety":{"commonSideEffects":[{"rate":"14-18","effect":"Headache"},{"rate":"11-14","effect":"Fatigue"},{"rate":"8-12","effect":"Diarrhea"},{"rate":"7-10","effect":"Nausea"},{"rate":"5-8","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1085282","moleculeType":"Small molecule","molecularWeight":"309.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Velpatasvir inhibits the NS5B polymerase through a non-nucleoside mechanism at a different binding site. Together, these complementary inhibitors provide potent and broad-spectrum activity against multiple HCV genotypes.","oneSentence":"Epclusa combines a nucleotide polymerase inhibitor (sofosbuvir) and a non-nucleoside polymerase inhibitor (velpatasvir) to block hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:12.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6), treatment-naïve and treatment-experienced patients"},{"name":"Hepatitis C virus infection in patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT06159504","phase":"EARLY_PHASE1","title":"Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania","status":"RECRUITING","sponsor":"Médecins du Monde","startDate":"2024-10-03","conditions":"Hepatitis C, RDT","enrollment":3040},{"nctId":"NCT03987503","phase":"PHASE4","title":"The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-07-01","conditions":"Hepatitis C, Chronic","enrollment":87},{"nctId":"NCT03570112","phase":"","title":"Transmission of Chronic Hepatitis C in Pregnancy","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2018-06-08","conditions":"Hepatitis C, Pregnancy Complications, Vertical Disease Transmission","enrollment":40},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT03057847","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Elizabeth Krans, MD","startDate":"2018-01-30","conditions":"Hepatitis C, Chronic, Opioid-use Disorder","enrollment":32},{"nctId":"NCT02510300","phase":"","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-10-21","conditions":"Hepatitis C Virus Infection","enrollment":461},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT04112303","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-10-16","conditions":"Hepatitis C Virus Infection","enrollment":37},{"nctId":"NCT03776760","phase":"","title":"Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2019-05-28","conditions":"Hepatitis C, Hepatitis, Liver Diseases","enrollment":600},{"nctId":"NCT02745535","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-05","conditions":"Chronic Hepatitis C","enrollment":77},{"nctId":"NCT02938013","phase":"PHASE4","title":"deLIVER: Direct Acting Antiviral Effects on the Liver","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"HCV Coinfection, Liver Disease, HIV","enrollment":15},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT05092074","phase":"","title":"Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-10-01","conditions":"Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment","enrollment":100},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT04997564","phase":"PHASE4","title":"The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2021-08","conditions":"Chronic Hepatitis C, Chronic Hepatitis B","enrollment":120},{"nctId":"NCT03818308","phase":"PHASE2","title":"Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2019-05-28","conditions":"Hepatitis C, Acute Hepatitis C","enrollment":20},{"nctId":"NCT04948801","phase":"","title":"SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-12-08","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT03501550","phase":"PHASE2","title":"Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2018-06-26","conditions":"Chronic Hepatitis C","enrollment":12},{"nctId":"NCT03389061","phase":"PHASE4","title":"Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet","status":"WITHDRAWN","sponsor":"Radboud University Medical Center","startDate":"2018-04-01","conditions":"HCV","enrollment":""},{"nctId":"NCT03820258","phase":"PHASE2","title":"Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-01-28","conditions":"Hepatitis C Virus Infection","enrollment":21},{"nctId":"NCT03513393","phase":"PHASE1","title":"Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-08-01","conditions":"Hepatitis C, Swallowing Disorder","enrollment":11},{"nctId":"NCT03022981","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-26","conditions":"Hepatitis C Virus Infection","enrollment":216},{"nctId":"NCT02533427","phase":"PHASE1","title":"Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-10-29","conditions":"HCV Infection","enrollment":15},{"nctId":"NCT03891550","phase":"PHASE3","title":"Micro-elimination of Hepatitis C Virus Infection in Uremics","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2019-05-13","conditions":"Hepatitis C","enrollment":135},{"nctId":"NCT03036852","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-03-22","conditions":"Chronic Hepatitis C","enrollment":59},{"nctId":"NCT02378935","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-17","conditions":"Hepatitis C Virus Infection","enrollment":205},{"nctId":"NCT02378961","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-16","conditions":"Hepatitis C Virus Infection","enrollment":128},{"nctId":"NCT02994056","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-23","conditions":"Hepatitis C Virus Infection","enrollment":32},{"nctId":"NCT03549312","phase":"PHASE4","title":"Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy","status":"UNKNOWN","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2018-02-01","conditions":"HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence","enrollment":25},{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT03118843","phase":"PHASE3","title":"Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-04-25","conditions":"Hepatitis C Virus Infection","enrollment":31},{"nctId":"NCT03074331","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-03-23","conditions":"Hepatitis C Virus Infection","enrollment":130},{"nctId":"NCT02607735","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT02639247","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":333},{"nctId":"NCT02607800","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-16","conditions":"Hepatitis C","enrollment":943},{"nctId":"NCT02639338","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":220},{"nctId":"NCT02996682","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-26","conditions":"Hepatitis C Virus Infection","enrollment":102},{"nctId":"NCT02536313","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-29","conditions":"Hepatitis C Virus Infection","enrollment":49},{"nctId":"NCT02728206","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-06-12","conditions":"Hepatitis C Virus Infection","enrollment":9},{"nctId":"NCT02671500","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-19","conditions":"Hepatitis C Virus Infection","enrollment":375},{"nctId":"NCT02781558","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-29","conditions":"Hepatitis C Virus Infection","enrollment":204},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT02201953","phase":"PHASE3","title":"Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":558},{"nctId":"NCT02346721","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-23","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT02300103","phase":"PHASE2","title":"Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-01","conditions":"Hepatitis C Virus Infection","enrollment":69},{"nctId":"NCT02722837","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-04","conditions":"Hepatitis C Virus Infection","enrollment":119},{"nctId":"NCT02480712","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-01","conditions":"Hepatitis C Virus Infection","enrollment":107},{"nctId":"NCT02201940","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":741},{"nctId":"NCT02220998","phase":"PHASE3","title":"Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-09","conditions":"Hepatitis C Virus Infection","enrollment":269},{"nctId":"NCT02201901","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":268},{"nctId":"NCT02822794","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-25","conditions":"Hepatitis C Virus Infection","enrollment":117},{"nctId":"NCT02781571","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Hepatitis C Virus Infection","enrollment":79},{"nctId":"NCT01858766","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Hepatitis C","enrollment":379},{"nctId":"NCT03250910","phase":"PHASE4","title":"Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2016-08-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus","enrollment":228},{"nctId":"NCT03018353","phase":"PHASE4","title":"Curing HCV in Incarcerated Patients","status":"UNKNOWN","sponsor":"San Francisco Department of Public Health","startDate":"2017-03-05","conditions":"Hepatitis C, Chronic","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":200,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Epclusa (SOF/VEL)","genericName":"Epclusa (SOF/VEL)","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epclusa combines a nucleotide polymerase inhibitor (sofosbuvir) and a non-nucleoside polymerase inhibitor (velpatasvir) to block hepatitis C virus replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), treatment-naïve and treatment-experienced patients, Hepatitis C virus infection in patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}